Loading...
Emergent BioSolutions Inc.
EBS•NYSE
Healthcare
Drug Manufacturers - Specialty & Generic
$7.17
$-0.30(-4.02%)
Emergent BioSolutions Inc. (EBS) Financial Performance & Income Statement Overview
Review Emergent BioSolutions Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-3.40%
↓ 3.40%
Operating Income Growth
85.04%
↑ 85.04%
Net Income Growth
74.94%
↑ 74.94%
Operating Cash Flow Growth
128.45%
↑ 128.45%
Operating Margin
-5.65%
↓ 5.65%
Gross Margin
31.60%
↑ 31.60%
Net Profit Margin
-13.71%
↓ 13.71%
ROE
-27.27%
↓ 27.27%
ROIC
-4.12%
↓ 4.12%
Emergent BioSolutions Inc. (EBS) Income Statement & Financial Overview
Review Emergent BioSolutions Inc.'s (EBS) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $189.30M | $293.80M | $254.70M | $300.40M |
| Cost of Revenue | $118.00M | $129.60M | $309.20M | $161.00M |
| Gross Profit | $71.30M | $164.20M | -$54.50M | $139.40M |
| Gross Profit Ratio | $0.38 | $0.56 | -$0.21 | $0.46 |
| R&D Expenses | $9.10M | $13.80M | $27.30M | $15.00M |
| SG&A Expenses | $60.80M | $76.60M | $77.30M | $84.60M |
| Operating Expenses | $80.80M | $96.70M | $104.60M | $99.60M |
| Total Costs & Expenses | $198.80M | $229.30M | $413.80M | $260.60M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $14.80M | $8.30M | $23.60M | $24.30M |
| Depreciation & Amortization | $26.00M | $26.40M | $29.40M | $28.80M |
| EBITDA | $13.20M | $177.10M | -$216.80M | $65.20M |
| EBITDA Ratio | $0.07 | $0.60 | -$0.51 | $0.23 |
| Operating Income | -$9.50M | $64.50M | -$159.10M | $39.80M |
| Operating Income Ratio | -$0.05 | $0.22 | -$0.62 | $0.13 |
| Other Income/Expenses (Net) | -$18.10M | $77.90M | -$110.70M | -$27.70M |
| Income Before Tax | -$27.60M | $142.40M | -$269.80M | $12.10M |
| Income Before Tax Ratio | -$0.15 | $0.48 | -$1.06 | $0.04 |
| Income Tax Expense | $3.70M | $27.60M | $13.30M | $3.10M |
| Net Income | -$31.30M | $114.80M | -$283.10M | $9.00M |
| Net Income Ratio | -$0.17 | $0.39 | -$1.11 | $0.03 |
| EPS | $0.00 | $2.16 | -$5.38 | $0.17 |
| Diluted EPS | $0.00 | $2.06 | -$5.38 | $0.17 |
| Weighted Avg Shares Outstanding | $0.00 | $53.10M | $52.60M | $52.20M |
| Weighted Avg Shares Outstanding (Diluted) | $0.00 | $55.60M | $52.60M | $52.20M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan